TransMedics Group Inc TMDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
TransMedics Reports Third Quarter 2026 Financial Results
TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics to Present at Upcoming Investor Conferences
TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
Trading Information
- Previous Close Price
- $68.98
- Day Range
- $76.50–88.44
- 52-Week Range
- $60.11–156.00
- Bid/Ask
- $87.00 / $88.00
- Shares Outstanding
- 34.73M
- Market Cap
- $3.06B
- Volume/Avg
- 4M / 864,056
Key Statistics
- Price/Earnings (Normalized)
- 23.76
- Price/Sales
- 4.52
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 898
- Website
- https://www.transmedics.com
Valuation
Metric | TMDX |
|---|---|
Price/Earnings (Normalized) | 23.76 |
Price/Book Value | 5.56 |
Price/Sales | 4.52 |
Price/Cash Flow | 19.29 |
Price/Earnings
TMDX
Financial Strength
Metric | TMDX |
|---|---|
Quick Ratio | 3.98 |
Current Ratio | 4.53 |
Interest Coverage | 3.94 |
Quick Ratio
TMDX
Profitability
Metric | TMDX |
|---|---|
Return on Assets (Normalized) | 13.62% |
Return on Equity (Normalized) | 36.64% |
Return on Invested Capital (Normalized) | 16.08% |
Return on Assets
TMDX
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|J<%<!%! | LOCK|^?>$% | $190B | |||
| Medtronic PLC MDT | LOCK|ytm&$z | LOCK|!g?K< | $130B | |||
| Stryker Corp SYK | LOCK|s&&^%&! | LOCK|&c | $124B | |||
| Boston Scientific Corp BSX | LOCK|ChGwnCg | LOCK|K!&S$ | $62B | |||
| Edwards Lifesciences Corp EW | LOCK|l>$q#d&L | LOCK|F?q$ | $59B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|<QFzqy | LOCK|<hj | $37B | |||
| Koninklijke Philips NV ADR PHG | LOCK|Kk | LOCK|nv | $30B | |||
| DexCom Inc DXCM | LOCK|KQL<VPl? | LOCK|znj^ | $30B | |||
| Steris PLC STE | LOCK|JJl&#C | LOCK|MP<# | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|BG$fg&GK | LOCK|PFp | $20B |
United States